Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche/Abbvie's Venclexta Outshines Agios IDH Inhibition In AML At ASH

Dec 05 2018

• By Emily Hayes

Acute myeloid leukemia a 3d-Render

Related Content

AML Master Protocol For Precision Medicine Developed By Nonprofit And US FDA

Dec 21 2016

AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces

Jan 06 2017

Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days

Jul 20 2018

More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay

Nov 22 2018

Related Companies

Roche Holding AG

AbbVie Inc.

Agios Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Additional Topics

Research & Development Cancer BioPharmaceutical

More from R&D

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window